Transcranial Magnetic Stimulation to Slow Down Cognitive Decline in Alzheimer's Disease
About this study
New amyloid-targeting drugs for Alzheimer's disease (AD) offer minimal or unclear efficacy and often cause adverse events, highlighting the need for new therapies. In recent years, repetitive transcranial magnetic stimulation (rTMS) has shown increasing success. A recent randomized, double-blind, sham-controlled, phase 2 demonstrated promising results from a 24-week rTMS treatment protocol targeting the precuneus. This brain region is considered a main hub of the human brain connectome and a prominent area of AD pathology. The results showed stable cognitive performance and increased brain activity in the treatment group, whereas the sham group worsened. A replication study is planned to further investigate the working mechanism of precuneus-rTMS in AD and to improve understanding of its therapeutic potential.
- Condition
- Alzheimer Disease, Alzheimer Disease, Early Onset
- Tested
- repetitive transcranial magnetic stimulation, sham repetitive transcranial magnetic stimulation
- Sponsor
- Willem de Haan
Who can join
- Age
- 50 to 85 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 8
- Minimum age: 50 years
- Maximum age: 85 years
- Study condition: Alzheimer Disease, Alzheimer Disease, Early Onset
- Biomarker-supported Alzheimer's disease (abnormal CSF p-tau/Aβ42 ratio of \> 0.023 or amyloid PET positive).
- Between 50 and 85 years old.
- Clinical Dementia Rating (CDR) score of 0.5 or 1.
- Mini-Mental State Examination (MMSE) score between 18 and 27.
- Presence of a caregiver.
Exclusion 7
- Medical history of neurodegenerative diseases other than AD, stroke, or epilepsy.
- Severe psychiatric dysregulation, hampering successful study participation and leading to possible cognitive impairment. Eligibility for participation will be based on clinical evaluation by an expert neurologist and/or psychiatrist.
- Extensive cerebrovascular damage on MRI classified as Fazekas level 2 or 3. Patients with abnormalities classified as Fazekas level 3 are excluded. For Fazekas level 2, patient's eligibility for participation will be evaluated by an expert neurologist.
- Presence of metal in the head or cranial/thoracic implants, including cochlear implants.
- Cholinesterase inhibitors with unstable dosage in the last 2 months.
- Extreme claustrophobia or metallic objects in or on the body, preventing MRI and MEG examination.
- Previous rTMS treatment (for blinding reasons).
Where
1 site, 1 recruiting
Amsterdam UMC
Amsterdam, Netherlands
Contact
-
Willem De Haan, PhD
020-444 8548 w.dehaan@amsterdamumc.nl
Potential match only. Final eligibility is determined by the study team.